Investing in Protalix BioTherapeutics Inc. (PLX): What You Must Know
Protalix BioTherapeutics Inc.’s filing revealed that its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct 19 ’23. In the deal valued at $1.40 per share,64,516 shares were bought. As a result of this transaction, Bashan Dror now holds 132,516 shares worth roughly $0.15 million. H.C. Wainwright reiterated its Protalix BioTherapeutics […]
H.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a Buy
Protalix BioTherapeutics Inc.’s filing revealed that its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct 19 ’23. In the deal valued at $1.40 per share,64,516 shares were bought. As a result of this transaction, Bashan Dror now holds 132,516 shares worth roughly $0.17 million. H.C. Wainwright reiterated its Protalix BioTherapeutics […]
PLX short interest surges, indicating growing pessimism among investors
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Protalix BioTherapeutics Inc. shares valued at $90,484 were purchased by Bashan Dror on Oct 19 ’23. At $1.40 per share, Bashan Dror acquired 64,516 shares. The insider’s holdings grew to 132,516 shares worth approximately […]
H.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a Buy
In a filing, Protalix BioTherapeutics Inc. revealed its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct 19 ’23. In the deal valued at $1.40 per share,64,516 shares were bought. As a result of this transaction, Bashan Dror now holds 132,516 shares worth roughly $0.16 million. H.C. Wainwright reiterated its Protalix […]
Protalix BioTherapeutics Inc. (PLX) stock is falling in premarket, Why is this happening?
Protalix BioTherapeutics, Inc. (NYSE American: PLX) a biopharmaceutical company focused on manufacturing recombinant therapeutic proteins with clinically improved profiles, confirmed receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning the Biologics License Application (BLA) attempting to fast-track approval for use of pegunigalsidase alfa (PRX‑102) for the potential treatment of adults effected […]
